Chronic hypoxia promotes hypoxia-inducible factor-1α–dependent resistance to etoposide and vincristine in neuroblastoma cells
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Hypoxia is widespread in solid tumors as a consequence of poorly structured tumor-derived neovasculature. Direct measurement of low oxygen levels in a range of adult tumor types has correlated tumor hypoxia with advanced stage, poor response to chemotherapy and radiotherapy, and poor prognosis. Little is known about the importance of hypoxia in pediatric tumors; therefore, we evaluated the effects of hypoxia on the response of the neuroblastoma cell lines SH-EP1 and SH-SY5Y to the clinically relevant drugs, vincristine, etoposide, and cisplatin. Short periods of hypoxia (1% O2) of up to 16 hours had no effect on drug-induced apoptosis or clonogenic survival. Prolonged hypoxia of 1 to 7 days leads to reduction in vincristine- and etoposide-induced apoptosis in SH-SY5Y and SH-EP1 cells, and this was reflected in increased clonogenic survival under these conditions. Neither short-term nor prolonged hypoxia had any effect on the clonogenic response to cisplatin in SH-SY5Y cells. Hypoxia-inducible factor-1 (HIF-1) α was stabilized in these cell lines within 2 hours of hypoxia but was no longer detectable beyond 48 hours of hypoxia. Up-regulation of carbonic anhydrase IX showed HIF-1α to be transcriptionally active. Down-regulation of HIF-1α by short hairpin RNA interference and the small-molecule 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole reduced hypoxia-induced drug resistance. These results suggest that prolonged hypoxia leads to resistance to clinically relevant drugs in neuroblastoma and that therapies aimed at inhibiting HIF-1α function may be useful in overcoming drug resistance in this tumor. [Mol Cancer Ther 2006;5(9):2241–50]
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several IHC-based studies have identified a correlation between high HIF-1α and low tumor stage, and a more favorable prognosis, whereas HIF-2α was correlated to unfavorable prognosis and high tumor stage [39].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [39]
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535 · cited 1×
“Under hypoxic conditions, this interaction is disrupted, allowing dimerization with HIF-1h and transactivation of target genes (7).”
BackgroundThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 1×
“The ubiquitinylation and targeting for degradation of HIF-1a is mediated through its binding to the protein product of the von Hippel-Lindau tumor suppressor gene under conditions of normal oxygen tension (5, 6).”
BackgroundHypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828 · cited 1×
“1% in head and neck carcinoma (30); thus, there will be”
BackgroundTumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662 · cited 2×
“A, Western blot showing levels of HIF1a in stable shRNA interference knockdown clones of SH-EP1 (1) and SH-SY5Y (3) cells.”
BackgroundMatthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898 · cited 2×
“amplification of the oncogene MYCN, which correlates with poor outcome (1).”
BackgroundHypoxia-inducible expression of tumor-associated carbonic anhydrases.
Wykoff, C. C., Beasley, N. J. P., Watson, P. H., Turner, K., Pastorek, J., Sibtain, A., Wilson, G. D., Turley, H., Talks, K., Maxwell, P. H., et al. (2000) · PubMed · Cited by 1,490
Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors
Moeller, B. J., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00115-1 · Cited by 996 · cited 1×
“The differential effect of HIF-1a inhibition in relation to the timing of cytotoxic drug dose is mirrored by the relationship between HIF-1a inhibition and radiosensitivity (39).”
BackgroundTanimoto, K., Makino, Y., Pereira, T., & Poellinger, L. (2000) · The EMBO Journal · doi:10.1093/emboj/19.16.4298 · Cited by 928 · cited 1×
“The ubiquitinylation and targeting for degradation of HIF-1a is mediated through its binding to the protein product of the von Hippel-Lindau tumor suppressor gene under conditions of normal oxygen tension (5, 6).”
Background
Research works printed but not linked: 2
- Sowter HS, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of hypoxic induction of death factors BNIP3 and NIX in human tumours. Cancer Res 2001;61:6669–73.
- Ross RA, Spengler BA, Biedler JL. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst 1983;71:741–9.
Cited by
Rohwer, N., & Cramer, T. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.03.001 · Cited by 608
Circumventing Tumor Resistance to Chemotherapy by Nanotechnology
Liang, X.-J., Chen, C., Zhao, Y., & Wang, P. C. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_21 · Cited by 330
“For example, the chronic influence of hypoxia may lead to etoposide and vincristine resistance by modifying gene expression of HIF-1 (36).”
Revisiting the HIF switch in the tumor and its immune microenvironment.
Cowman, S. J., & Koh, M. Y. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.10.004 · Cited by 256
Sullivan, R., Paré, G. C., Frederiksen, L. J., Semenza, G. L., & Graham, C. H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0198 · Cited by 243
Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells
Wu, H.-M., Jiang, Z.-F., Ding, P.-S., Shao, L.-J., & Liu, R.-Y. (2015) · Scientific Reports · doi:10.1038/srep12291 · Cited by 179
Metadata
- Authors
- Hussein, D., Estlin, E. J., Dive, C., & Makin, G. W. J.
- Affiliations
- Cancer Research UK Manchester Institute (GB)
- Royal Manchester Children's Hospital (GB)
- University of Manchester (GB)
- Venue
- Molecular Cancer Therapeutics
- Published
- 2006-09-01
- Volume
- 5
- Issue
- 9
- Pages
- 2241-2250
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2129497554
- Cited by
- 80
- References
- 44
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 7 · 2020: 3 · 2019: 5 · 2018: 2 · 2017: 5 · 2016: 4 · 2015: 5 · 2014: 4 · 2013: 2 · 2012: 3
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- tumor hypoxia, neuroblastoma, HIF-1α, etoposide resistance, vincristine resistance, cisplatin, apoptosis, clonogenic survival, carbonic anhydrase IX, HIF-1α stabilization, HIF-1α inhibition
- MeSH terms
- Cisplatin, Etoposide, Humans, Indazoles, Neuroblastoma, Vincristine, Down-Regulation, Cell Hypoxia, Apoptosis, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-bcl-2, Cell Line, Tumor, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronic hypoxia promotes hypoxia-inducible factor-1α–dependent resistance to etoposide and vincristine in neuroblastoma cells. https://app.cochat.ai/papers/10.1158/1535-7163.mct-06-0145
- The paper
- Hussein, D., Estlin, E. J., Dive, C., & Makin, G. W. J. (2006). Chronic hypoxia promotes hypoxia-inducible factor-1α–dependent resistance to etoposide and vincristine in neuroblastoma cells. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-06-0145
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.